Investor company presentation February 2026 Forward-looking statements The information in this presentation contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "intend", "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements ...

Core Viewpoint - Idorsia Ltd is positioned for profitability and growth with two products entering the value-acceleration phase and a promising pipeline of innovative medicines [2][3] Highlights in 2025 - Idorsia achieved strong operational progress, including the global expansion of QUVIVIQ, which is on track to meet sales guidance of approximately CHF 130 million [7] - The company completed debt restructuring and secured new financing, extending its cash runway into 2028 [7] - Clinical validation for its synthetic glycan vaccine technology and initiation of a proof-of-concept trial with a CCR6 antagonist were also notable achievements [7] Areas of Focus in 2026 - The company aims to make QUVIVIQ the standard of care for insomnia and maximize the value of TRYVIO/JERAYGO for uncontrolled hypertension [3][7] - Plans include advancing lucerastat for Fabry Disease registration and progressing the Phase 2 proof-of-concept immunology portfolio [7] - Idorsia will continue to explore partnerships and new sales models for QUVIVIQ, as well as support potential descheduling in the US [7]